The estimated Net Worth of Andre Turenne is at least $4.07 Milion dollars as of 11 February 2021. Mr. Turenne owns over 7,977 units of Voyager Therapeutics Inc stock worth over $931,795 and over the last 6 years he sold VYGR stock worth over $293,264. In addition, he makes $2,844,090 as President, Chief Executive Officer a Director at Voyager Therapeutics Inc.
G has made over 3 trades of the Voyager Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,977 units of VYGR stock worth $60,226 on 11 February 2021.
The largest trade he's ever made was selling 10,705 units of Voyager Therapeutics Inc stock on 21 January 2020 worth over $143,019. On average, G trades about 3,641 units every 48 days since 2018. As of 11 February 2021 he still owns at least 148,375 units of Voyager Therapeutics Inc stock.
You can see the complete history of Mr. Turenne stock trades at the bottom of the page.
G. Andre Turenne serves as President, Chief Executive Officer, Director of the Company since July 2018. Prior to joining Voyager, Mr. Turenne held various positions at Sanofi, a biopharmaceutical company, including serving as Senior Vice President, Global Head of Business Development and Licensing, from November 2015 to March 2018, where he was responsible for partnering activities across all of Sanofi’s business units. Prior to that role, Mr. Turenne served as General Manager of Sanofi Genzyme Australia and New Zealand from January 2015 to November 2015 and previously served as Global Head of Strategy and Business Development for Genzyme from September 2012 to January 2015. Prior to its acquisition by Sanofi, Mr. Turenne served in several business development and commercial operations roles at Genzyme Corporation, a biopharmaceutical company, from 2006 to 2011. He began his career in the industry as a consultant at Kendall Strategies, the consulting arm of Feinstein Kean Healthcare, now part of Ogilvy. Mr. Turenne received a B.A. from Kalamazoo College and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.
As the President, Chief Executive Officer a Director of Voyager Therapeutics Inc, the total compensation of G Turenne at Voyager Therapeutics Inc is $2,844,090. There are 2 executives at Voyager Therapeutics Inc getting paid more, with Omar Khwaja having the highest compensation of $3,815,770.
G Turenne is 46, he's been the President, Chief Executive Officer a Director of Voyager Therapeutics Inc since 2018. There are 14 older and 1 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
Andre's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC.,, 75 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 a Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: